Immuno-oncology company Agenus Inc (NASDAQ: AGEN) reported on Wednesday the start of its Phase I clinical trial of an undisclosed antibody candidate.
The company's Phase I clinical trial was initiated by its partner, Merk.
Under the terms of the agreement, Agenus received a USD4m milestone payment and is entitled to receive up to an additional USD95m in success milestones from Merck.
This milestone is reportedly the second under the collaboration originally announced in April 2014.
Pursuant to the agreement, Merck is responsible for all product development expenses for the antibody candidate, and Agenus is eligible to receive up to an additional USD95m in milestone payments, as well as royalties on worldwide product sales.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval